Free Trial
NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Avenue Therapeutics logo
$0.25 +0.02 (+9.52%)
As of 05/2/2025 12:50 PM Eastern

About Avenue Therapeutics Stock (NASDAQ:ATXI)

Key Stats

Today's Range
$0.24
$0.25
50-Day Range
$0.23
$1.25
52-Week Range
$0.23
$5.97
Volume
7,012 shs
Average Volume
139,040 shs
Market Capitalization
$793,800.00
P/E Ratio
0.01
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Avenue Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

ATXI MarketRank™: 

Avenue Therapeutics scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Avenue Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avenue Therapeutics is 0.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.97.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avenue Therapeutics is 0.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.79.

  • Price to Book Value per Share Ratio

    Avenue Therapeutics has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avenue Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ATXI.
  • Dividend Yield

    Avenue Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Avenue Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ATXI.
  • Search Interest

    1 people have searched for ATXI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    6 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

  • Read more about Avenue Therapeutics' insider trading history.
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Stock News Headlines

Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
See More Headlines

ATXI Stock Analysis - Frequently Asked Questions

Avenue Therapeutics' stock was trading at $2.00 on January 1st, 2025. Since then, ATXI shares have decreased by 87.4% and is now trading at $0.2520.
View the best growth stocks for 2025 here
.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its earnings results on Friday, August, 9th. The company reported ($6.43) EPS for the quarter, missing the consensus estimate of ($1.05) by $5.38.

Shares of Avenue Therapeutics reverse split on Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Avenue Therapeutics (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/09/2024
Today
5/04/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATXI
Fax
N/A
Employees
4
Year Founded
2015

Profitability

Trailing P/E Ratio
0.01
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.92 per share
Price / Book
0.13

Miscellaneous

Free Float
2,017,000
Market Cap
$793,800.00
Optionable
Not Optionable
Beta
-0.01

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ATXI) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners